Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
20.40
+1.60 (8.51%)
At close: Aug 13, 2025, 4:00 PM
20.60
+0.20 (0.98%)
After-hours: Aug 13, 2025, 7:11 PM EDT
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $611.09M in the quarter ending June 30, 2025, with 68.38% growth. This brings the company's revenue in the last twelve months to $2.48B, up 64.89% year-over-year. In the year 2024, Sarepta Therapeutics had annual revenue of $1.90B with 52.97% growth.
Revenue (ttm)
$2.48B
Revenue Growth
+64.89%
P/S Ratio
0.80
Revenue / Employee
$1,808,696
Employees
1,372
Market Cap
1.99B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SRPT News
- 3 hours ago - Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment - Business Wire
- 10 hours ago - SAREPTA STOCK: Lose Money on Your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investment? Contact BFA Law before the August 25 Legal Deadline - GlobeNewsWire
- 2 days ago - SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT - PRNewsWire
- 2 days ago - SRPT COURT NOTICE: Sarepta Therapeutics Investors may have been Affected by Fraud -- Contact BFA Law before August 25 if You Suffered Losses (NASDAQ:SRPT) - GlobeNewsWire
- 2 days ago - These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More - Barrons
- 7 days ago - Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments - Business Wire
- 13 days ago - Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results - Business Wire
- 13 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT - PRNewsWire